In:
Obstetrical & Gynecological Survey, Ovid Technologies (Wolters Kluwer Health), Vol. 78, No. 1 ( 2023-1), p. 14-16
Abstract:
(Abstracted from Am J Obstet Gynecol 2022;227:87.e1–87.e14) Although historically prenatal genetic screening has relied on ultrasound and maternal serum analyses, recent years have seen a 15% annualized growth rate of the fetal cell-free DNA (cfDNA) test since its introduction in 2011. Despite the high accuracy of these screens, sensitive information within their results regarding current and future health for both the pregnant patient and the fetus renders the leftover samples as valuable for research and development.
Type of Medium:
Online Resource
ISSN:
1533-9866
,
0029-7828
DOI:
10.1097/01.ogx.0000912584.17745.e6
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2023
detail.hit.zdb_id:
2043471-6
Bookmarklink